The GLP is committed to full transparency. Download and review our Annual Report.

Are we entering the age of $1 million medicine?

| January 14, 2013

More than a quarter of the new medicines approved in the United States last year were designated for rare or so-called orphan diseases. While that’s good news for people suffering from these conditions, the price tags can be overwhelming: The new gene therapy for lipoprotein lipase deficiency is likely to cost more than $1 million per patient when it goes on sale in Europe this summer.  Increasingly, healthcare providers are having to balance the acute needs of the few against the wider interests of society, within constrained budgets.

View the original article here: Are we entering the age of $1 million medicine?


The GLP featured this article to reflect the diversity of news, opinion and analysis. The viewpoint is the author’s own. The GLP’s goal is to stimulate constructive discourse on challenging science issues.

News on human & agricultural genetics and biotechnology delivered to your inbox.
Optional. Mail on special occasions.

Send this to a friend